Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-25T13:31:24.422Z Has data issue: false hasContentIssue false

117 - Quetiapine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Seroquel, Ketipinor, Seroquel XR

Generic?

• Yes

Class

• Atypical antipsychotic

Commonly Prescribed for

(FDA approved in bold)

Schizophrenia

Bipolar disorder (depression and mania) as monotherapy or adjunct to lithium and divalproex

Adjunctive therapy for major depressive disorder (extended-release only)

• Psychosis associated with Parkinson’s disease (PD) or dementia with Lewy bodies (DLB)

• Augmentation for refractory obsessivecompulsive disorder

• Autism

• Alcoholism

• Gilles de la Tourette syndrome (GTS)

• Insomnia

• Anxiety

How the Drug Works

• A benzothiazepine derivative. At lower dose, quetiapine is H1,2 and α1-adrenergic blocker. At higher dose, quetiapine starts blocking more D2,3 (as other neuroleptics) and 5-HT2A receptors

• Lower D2/3 binding constant than haloperidol reduces its risk of motor side effects

• Binding to other receptors may improve depression and cognitive problems

How Long Until It Works

• Schizophrenia/bipolar: may be effective in days, more commonly takes weeks or months to determine best dose and achieve best clinical effect. Usually 4–6 weeks

• Insomnia: may be effective immediately

If It Works

• Continue to use at lowest required dose. Most patients with schizophrenia see a reduction in psychosis with quetiapine (and other neuroleptics), but some patients, including many with PD and DLB, may improve more than 50%

If It Doesn't Work

• Increase dose

• In psychosis related to PD or DLB, reduce dose or eliminate offending medications, such as dopamine agonists or amantadine

• If not effective consider changing to clozapine. In PD and DLB, avoid long-term use of conventional antipsychotics

• Insomnia: if no sedation occurs despite adequate dosing, change to another agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Patients with affective disorders, such as bipolar disorder, may respond to moodstabilizing AEDs, lithium, or benzodiazepines. In PD and DLB, cholinesterase inhibitors may improve symptoms (particularly in DLB)

Tests

• Prior to starting treatment and periodically during treatment, monitor weight, blood pressure, lipids, and fasting glucose due to risk of metabolic syndrome

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 432 - 435
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Quetiapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.118
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Quetiapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.118
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Quetiapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.118
Available formats
×